Basal cell carcinoma: mixed (syn. multicomponent or multifocal)

LAST UPDATED: Jan 19, 2026

Patient Information Leaflet
Link: Basal cell carcinoma

https://www.pcds.org.uk/patient-info-leaflets/basal-cell-carcinoma

Introduction

A mixed basal cell carcinoma (BCC) is a BCC with more than one histological subtype.

This chapter is set out as follows:


Aetiology

  • Up to one-third of all BCC have mixed histological features
     
  • Evidence suggests that mixed BCC originate from one single focus (monoclonal) rather than multiple independent sites, despite their often disconnected histological appearance; the term 'multifocal BCC' should be abandoned. It is likely that as this group of BCC evolve there is phenotypic transformation of the malignant cells 

Clinical findings

  • May be poorly defined due to the presence of different subtypes of BCC and the fact that more aggressive histological features, such as infiltrative pattens, are common in such lesions

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Management

  • The lesion should be managed in line with which of the described histological subtypes is the most aggressive, for example, a lesion showing both nodular and infiltrative components should be managed as an infiltrative BCC
     
  • For more information refer to the related chapter Basal cell carcinoma - an overview

Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco